Supernus Pharmaceuticals Inc. (SUPN) is all set to report results of its final phase III study for SPN-812 in patients 12-17 years old, dubbed P304, for the treatment of attention deficit hyperactivity disorder on Thursday, March 28, 2019, at approximately 8:00 a.m. ET.
from RTT - Biotech https://ift.tt/2TXXTBA
via IFTTT
No comments:
Post a Comment